Greenland Mines Ltd. (GRML)
Oxford Ledge is still expanding full research coverage of GRML. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Greenland Mines develops medicines for cancer and neurodegenerative diseases through drug and gene therapy platforms, and operates in minerals mining.
Source: 10-K
SEC filings
- 8-K 4.01; Financial statements and exhibits 2026-07-08
- 8-K 4.01; Financial statements and exhibits 2026-06-29
- 8-K 3.02; Financial statements and exhibits 2026-06-25
- DEF 14A Proxy statement for shareholder vote 2026-06-22
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-06-22
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for GRML. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GRML in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.